Mutation ID'd in Waldenstrom's macroglobulinemia

August 30, 2012

(HealthDay)—MYD88 L265P is a common, recurring mutation in patients with Waldenström's macroglobulinemia, according to a study published in the Aug. 30 issue of the New England Journal of Medicine.

Steven P. Treon, M.D., Ph.D., from the Dana Farber Cancer Institute in Boston, and colleagues performed whole-genome sequencing of lymphoplasmacytic lymphoma (LPL) cells in 30 patients with Waldenström's macroglobulinemia. The findings were validated using Sanger sequencing in an expanded cohort of patients with LPL, those with other B-cell disorders that have some of the same features as LPL, and healthy donors.

The researchers identified a somatic variant (T→C) in LPL cells at position 38182641 at 3p22.2 among the patients with Waldenström's macroglobulinemia. This variant was seen in all samples from 10 patients with paired and in 17 of 20 samples from patients with unpaired samples. The variant predicted an alteration in an amino acid (L265P) in MYD88, which led to IRAK-mediated NF-κB signaling. MYD88 L265P was identified using Sanger sequencing in tumor samples from 49 of 54 patients with Waldenström's macroglobulinemia and in all three patients with non- M (IgM)-secreting LPL. In paired normal tissue samples from patients with Waldenström's macroglobulinemia or non-IgM LPL and in from healthy donors, MYD88 L265P was absent.

"MYD88 L265P is a commonly recurring mutation in patients with Waldenström's macroglobulinemia that can be useful in differentiating Waldenström's macroglobulinemia and non-IgM LPL from B-cell disorders that have some of the same features," Treon and colleagues conclude.

Several authors are employees of Complete Genomics.

Explore further: Common blood disorder may not be linked to as many serious diseases

More information: Full Text (subscription or payment may be required)

Related Stories

Study sheds light on triglyceride metabolism

July 7, 2010

New findings reported in the July issue of Cell Metabolism are offering new leads as to why some people might suffer from high levels of triglycerides. High triglycerides are a risk factor for atherosclerosis and cardiovascular ...

Using a molecular switch to turn on cancer vaccines

March 7, 2011

The immune system is capable of recognizing tumor growth, and naturally mounts an anti-cancer defense. Dendritic cells (DCs) can take up tumor-derived molecules (antigens) and present them to T cells, and those "primed" T ...

Fewer mitochondria in offspring of parents with diabetes

March 26, 2012

(HealthDay) -- Normal-weight, insulin-resistant individuals whose parents have type 2 diabetes have fewer mitochondria in their muscles due to lower expression of lipoprotein lipase (LPL), according to a study published in ...

Recommended for you

Molecularly shutting down cancer cachexia

August 30, 2016

Healthy fat tissue is essential for extended survival in the event of tumor-induced wasting syndrome (cachexia). In Nature Medicine, researchers at Helmholtz Zentrum München show that selective manipulation of an enzyme ...

Radiologists detect breast cancer in 'blink of an eye'

August 29, 2016

A new study by investigators at Brigham and Women's Hospital in collaboration with researchers at the University of York and Leeds in the UK and MD Andersen Cancer Center in Texas puts to the test anecdotes about experienced ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.